Asset profile

Quizartinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (4)
May 2027 (2)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-05-01 · NCT03793478 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT04047641 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT04128748 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
January 2028 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-01 · NCT03661307 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT06262438 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-06 · NCT06824168 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (2)
April 2030 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT07478991 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (1)
Phase 3LeukemiaActive not recruiting
Est. primary completion 2030-06-26 · NCT06578247 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.